Treatt PLC Lowers Full-Year Forecast Amid Challenges, Announces Share Buyback
Treatt lowers FY forecast due to high citrus prices & soft US demand, launches £5m share buyback to signal strategic confidence.
This article covers information on Treatt PLC.
LON:TETThe Numbers Tell a Story (But Not the Whole Story)
Treatt’s latest trading update is a classic case of “yes, but…” – a cocktail of short-term headwinds and strategic ambition that leaves investors with plenty to chew on. Let’s unpack this like a master blender dissecting a new flavour profile.
Key Financial Snapshot
- Revenue: £64.2m (down 11% vs H1 2024)
- Adjusted EBITDA: ~£6.6m (from £10.6m)
- Profit Before Tax & Exceptionals: ~£3.6m (halved from £7.6m)
- Net Cash: £0.9m (swinging from net debt position)
The Bitter Notes in the Blend
Three main factors are leaving a tart aftertaste:
1. Citrus Squeeze
Sustained high prices led customers to reformulate recipes – think less fresh orange oil, more cost-effective alternatives. Treatt’s value-added citrus volumes took a 10% hit.
2. America’s Fizzling Thirst
US consumers appear to be literally losing their bottle. Softening demand for carbonated drinks (and geopolitical jitters) hit Premium category sales – down 13% in constant currency.
3. The Tariff Tango
While not yet quantified, the company’s watching US trade tariffs like a hawk. Though their global manufacturing footprint provides some salsa to this dance.
The Counterbalance: Strategic Sweeteners
Management isn’t just crying into their cold brew. Two moves stand out:
£5m Share Buyback: Confidence or Conundrum?
Initiating a buyback while downgrading forecasts is… interesting. It signals:
- Belief that shares are undervalued
- Discipline in capital allocation (net cash position helps)
- Limited M&A opportunities at sensible valuations?
As one City wag might say: “Returning cash when growth stutters? Bold choice, Cotton.”
Eastern Promise: Shanghai Innovation Centre
Treatt’s China play could be the dark horse here. With:
- New Shanghai hub opening this year
- Growing local sales team
- Treattzest products gaining traction
This isn’t just expansion – it’s embedding in the world’s fastest-growing flavour market.
The Outlook: Storm Clouds With Silver Linings
Revised guidance of £16m-£18m PBTE (down from consensus £19m+) stings, but let’s note:
Self-Help Measures Bubbling Through
- Flat admin costs despite inflation
- Efficiency gains from French lab/simplification drives
- New website (launching May) enhancing customer ops
Premium’s Summer Promise
Remember – 55% of Premium sales typically land in H2. With new North American client wins and low/no-sugar trends accelerating, the fizz could return.
Final Pour: Hold the Panic
CEO David Shannon’s messaging is clear: “Short-term pain, medium-term gain.” The question for investors – is this a structural shift or temporary palate cleanse?
Key watch points:
- H2 Premium sales performance (June-August critical)
- Citrus price trajectory
- China revenue acceleration post-Shanghai launch
One to watch like a barista monitoring their cold brew tap – patience required, but potential for rich returns when the extraction’s right.
Related
Keep reading
Investing
Ten Technologies Preliminary Results 2026: Record EBITDA and Member Growth
Ten Technologies delivered record 2026 results as active members rose 23% and adjusted EBITDA increased 10% to £16.1 million.
JoshuaNovember 11, 2026
Investing
Winvia Entertainment completes The Online Giveaway Guys acquisition
Winvia Entertainment has completed its purchase of The Online Giveaway Guys' business and key assets, excluding liabilities, cash and receivables.
JoshuaNovember 10, 2026
Investing
RUA Life Sciences reaches positive adjusted EBITDA as Structural Heart spin-out reshapes the group
RUA Life Sciences expects £5.5 million revenue and £0.3 million adjusted EBITDA, but ABISS weakness and lower cash warrant attention.
JoshuaNovember 9, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.